REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Lex Fridman

Influencer

Lex Fridman

About

Alexei "Lex" Fridman (; born 15 August 1983) is an American computer scientist and podcaster. Since 2018, he has hosted the Lex Fridman Podcast, where he interviews notable figures from various fields such as science, technology, sports, the arts, and politics. Fridman rose to prominence in 2019 after Elon Musk praised a study Fridman authored at MIT, which concluded that drivers remained focused while using Tesla's semi-autonomous driving system. The study was not peer-reviewed and was criticized by AI experts. That year Fridman transitioned to an unpaid role at MIT AgeLab, and since 2022 has worked as a research scientist at the MIT Laboratory for Information and Decision Systems (LIDS). As of February 2024, Fridman lives in Texas and is employed at MIT.

Videos

The insane difficulty of reverse engineering video codecs | Lex Fridman Podcast

VLC turned down $30+ million dollars to keep VLC ad-free | Lex Fridman Podcast

Future of holograms, brain signal playback, smell, and touch in multimedia software | Lex Fridman

How FFmpeg works - explained by FFmpeg & VLC developers | Lex Fridman Podcast

Linus Torvalds built Git in 10 days | Lex Fridman Podcast

The controversial FFmpeg and Libav split saga explained | Lex Fridman Podcast

How FFmpeg revolutionized the Internet: The origin story of FFmpeg | Lex Fridman Podcast

How controversy on Twitter/X helps solve problems | Lex Fridman Podcast

Regret is a tax on your mind - I regret nothing | Lex Fridman Podcast

Fast robot teleoperation (at ultra-low 8ms latency): Kyber explained | Lex Fridman Podcast